GDTC
CytoMed Therapeutics LimitedNASDAQHealthcare$1.06+7.27%ClosedMarket Cap: $12.4M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
2.23
P/S
48.18
EV/EBITDA
-5.16
DCF Value
$0.33
FCF Yield
-18.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
109.7%
Operating Margin
-861.8%
Net Margin
-1082.5%
ROE
-47.9%
ROA
-42.5%
ROIC
-36.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2025 | $105.7K | 93.1% | $-510.6K | $-882.3K | $-0.07 | — |
| Q1 2025 | $100.0K | 93.1% | $-483.2K | $-835.0K | $-0.07 | — |
| Q4 2024 | $52.4K | 174.9% | $-1.2M | $-1.1M | $-0.09 | — |
| FY 2024 | $52.0K | 100.7% | $-2.6M | $-1.9M | $-0.16 | — |
| Q3 2024 | $108.6K | 89.7% | $-397.8K | $-555.7K | $-0.05 | — |
| Q2 2024 | $82.7K | 99.0% | $-1.4M | $-808.0K | $-0.07 | — |
| Q1 2024 | $83.1K | 99.0% | $-393.3K | $-403.5K | $-0.04 | — |
| Q4 2023 | $84.7K | 98.9% | $-331.0K | $-748.2K | $-0.06 | — |
| FY 2023 | $290.6K | 131.4% | $-3.2M | $-3.1M | $-0.29 | — |
| Q3 2023 | $81.7K | 98.9% | $-663.2K | $-722.3K | $-0.06 | — |
| Q2 2023 | $105.1K | -44.6% | $-1.2M | $-1.6M | $-0.14 | — |
| Q1 2023 | $106.8K | 97.9% | $-762.5K | $-810.8K | $-0.08 | — |